Morphic Holding, Inc

Alkermes is a worldwide pharmaceutical company that develops controlled, sustained-release injectable drugs using with its trademark ProLease and Medisorb technologies. Located in Massachusetts, the company also develops inhaled formulations from its proprietary pulmonary technology. Alkermes has partnered with Johnson & Johnson to develop Riserpdal Consta, an antipsychotic drug used in the treatment of schizophrenia. Risperdal Consta is approved for sale in more than 50 countries that include the United States, United Kingdom and Germany. In addition to a host of partnered products, the ocmpany is also active in the development of several promising proprietary products, such as Vivitrex, a long-acting injectable form of naltrexone for alcohol dependence. Alkermes is headquartered in Cambridge, Mass.

Keros Therapeutics, Inc is a biopharmaceutical company based in Lexington, MA that is dedicated to developing innovative therapies for patients with disorders related to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. With a focus on hematological, pulmonary cardiovascular, and neuromuscular conditions, Keros leverages its deep expertise in TGF-β science to develop and commercialize novel therapeutics that have the potential to modulate TGF-β signaling and provide disease-modifying benefits for patients in need. Driven by a passion for science and a commitment to their mission, Keros is at the forefront of cellular growth repair, aiming to shift the treatment paradigm for a wide range of patients. By harnessing the power of TGF-β biology, Keros is dedicated to advancing therapies that can unlock new possibilities for patients and improve their quality of life.Generated from the website

Parexel International, based in Newton, MA, is a leading Contract Research Organization (CRO) offering end-to-end solutions in biotech and therapeutic expertise for the development of life-changing medicines. With a focus on patient impact, Parexel provides services ranging from portfolio optimization and regulatory strategy to phase I-IV clinical trials and market access planning. The company's diverse capabilities include portfolio management, early development and innovation, integrated clinical development, approval and access, value substantiation, and lifecycle management. Parexel's global reach, operational excellence, and commitment to leveraging cutting-edge technologies make them a trusted partner in advancing healthcare and improving patient outcomes. Generated from the website